Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest respiratory failure Stories

2012-04-04 10:12:42

Although data indicate that between 2003-2009 there was a substantial decline in the U.S. in hospitalizations for pneumonia and inpatient deaths, analysis suggests that trends in documentation and diagnostic coding, rather than improvements in actual outcomes, may explain much of the observed changes, according to a study in the April 4 issue of JAMA. Pneumonia is a leading cause of illness and death among U.S. adults, resulting in more than 1 million annual hospital admissions and...

2012-03-21 06:24:26

HAMPTON, N.J., March 21, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the Center for Devices and Radiological Health (CDRH) branch of the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for compatibility of its INOMAX drug-delivery systems with three additional respiratory care devices. The INOMAX DS and the INOMAX DSIR have now been validated...

2012-03-07 06:45:00

WARRINGTON, Pa., March 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will hold a conference call for investors today at 10 a.m. EST to discuss its March 6th announcement that SURFAXIN (lucinactant) has been approved by the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first FDA-approved...

2012-03-06 15:10:00

WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal...

2012-02-27 09:17:00

HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD). The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule. The...

2011-10-26 10:29:00

MECHANICSBURG, Pa., Oct. 26, 2011 /PRNewswire/ -- One out of three U.S. adults plan to skip their flu shot this year, according to an Opinion Research/Select Medical telephone poll. Against that backdrop, two top clinical leaders in long-term acute care released a statement today reminding the American public that influenza season can be a deadly time for those suffering from a chronic lung disease such as asthma or COPD (Chronic Obstructive Pulmonary Disease). Such patients need to take...

2011-10-04 07:00:00

WAYNE, N.J., Oct. 4, 2011 /PRNewswire/ -- MAQUET, a global leader in medical systems, today announced that the company has received the 2011 European Association of Cardio-Thoracic Surgery (EACTS) Techno College Innovation Award for its revolutionary CARDIOHELP System. Approved for use in the United States and Europe, CARDIOHELP is the world's smallest portable heart-lung support system providing extracorporeal life support to replace or support a patient's circulation and respiration. It...

2011-08-16 12:49:00

STEVENSVILLE, Md., Aug. 16, 2011 /PRNewswire-USNewswire/ -- Vapotherm, a privately held manufacturer of respiratory care devices for hospital and home use, announced today that its Precision Flow® system has been validated by Ikaria, Inc. and cleared by the FDA for the administration of nitric oxide via high flow nasal cannula. The product is part of Vapotherm's High Flow Specialty Gas Program for optimal conditioning of breathing gases. Hypoxic respiratory failure...

2011-08-16 08:00:00

Receives $2.3 million from Bill & Melinda Gates Foundation to complete development of affordable respiratory support device SEATTLE, Aug. 16, 2011 /PRNewswire-USNewswire/ -- Seattle Children's Research Institute today announced the receipt of a two-year, $2.3 million grant from the Bill & Melinda Gates Foundation to complete prototype development of its new respiratory support device, called Seattle Children's Positive Airway Pressure (Sea-PAP.) Sea-PAP, designed to be an...

2011-07-11 15:10:00

BEVERLY HILLS, Calif., July 11, 2011 /PRNewswire/ -- OXIS International, Inc. (OTC/BB: OXIS.OB; Euronext Paris: OXI) today announced that it has formed a joint venture with John E. Repine, M.D. to develop ergothioneine as a potential intervention to treat and prevent Acute Lung Injury (ALI), including the most severe form of ALI known as Acute Respiratory Distress Syndrome (ARDS). The joint venture has the rights to patent-pending technology created by Dr. Repine covering the use of...